10th BenBedPhar Scientific meeting

Satellite meeting of the SFRR-I Conference (Galway, June 3-6) Unlocking NRF2 Research for Future Clinical Therapies

Location: Galway, Ireland

Participants: members of the Management Committee and Work Groups of the COST Action CA20121

Organizers and contact persons

Dr. Kasia Goljanek-Whysall,
Email: kasia.whysall@universityofgalway.ie

Dr. Antonio Cuadrado
Email: antonio.cuadrado@uam.es

Overview.

The European COST Action CA20121, titled “Bench to Bedside Transition for Pharmacological Regulation of NRF2 in Non-Communicable Diseases (BenBedPhar),” is organizing its 10^th scientific meeting as a satellite symposium of the Biennial conference of the International Society for Free Radical Research. For more information visit the official webpage: https://www.sfrrgalway2025.com/

Organizers.

Preliminary program:

Friday, 6th of June

Discovery and characterization of the KEAP1-NRF2 pathway Masayuki Yamamoto. Tohoku University, Tohoku Medical Megabank Organization, Sendai, Japan

15:50 – 16:20 | DPP3 as a modulator of NRF2-KEAP1 pathway: Insights from CRISPR-Cas9 knockout and gene expression analysis Ana Tomašić Paić, Marina Oskomić, Lea Barbarić, Mihaela Matovina (Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Zagreb, Croatia)

16:20 – 16:50 | NRF2 in dialogue with amp-activated kinase and cellular energy metabolism Shara Natalia Sosa Cabrera, Eleni Petsouki, Katrin Fischhuber, Manuel Matzinger, Elke H. Heiss (Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Vienna, Austria)

16:50 – 17:20 | Metabolic and immunological features of NRF2-activated cancers. Hozumi Motohashi. Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan

17:50 – 18:20 | Pharmacological inhibition of KEAP1 by cysteine-targeting electrophiles and non-electrophilic protein-protein interaction inhibitors . Miroslav Novak, Sharadha Dayalan Naidu, Dina Dikovskaya, Terry W. Moore, and Albena T. Dinkova-Kostova. Division of Cancer Research, University of Dundee School of Medicine, Dundee, U.K.

18:20 – 18:50 | Effects of dimethyl fumarate on plasma triglyceride levels and PPAR alpha gene expression in hypertriglyceridemic rats exposed to chronic crowding stress Iveta Bernatova, Michal Kluknavsky, Aybuke Bozkurt, Andrea Micurova, Anjum Anjum, Peter Balis (Centre of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovakia)

18:50 – 19:20 | Prevention of environmental stress and damage by activation of nuclear factor erythroid 2-related factor 2 (NRF2) and associated pathways Andreas Daiber (Center for Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University, German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany)

19:20 – 19:50 | Temporal assessment of the NRF2 antioxidant response signaling induced by air pollution exposure Claire Fayad, Alexey Afonin, Laura Mussalo, Riikka Lampinen, Pasi Jalava, Katja M. Kanninen (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland)

Saturday, 7th of June

09:00 – 09:30 | Sex differences in NRF2-mediated stress response and autophagy in MASLD and MASH models: Implications for therapeutic strategies. Brigitta Buttari (Istituto Superiore di Sanità, Rome, Italy)

09:30 – 10:00 | Advances and challenges translating the NRF2 science to the clinic Ian Copple (University of Liverpool, Liverpool, UK)

10:00 – 10:30 | Biomarkers of NRF2 activation in non-small cell lung carcinoma Anna-Lisa Levonen (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland)

11:00 – 11:30 | Preclinical testing of dimethyl fumarate as a repurposing therapeutic approach for early age-related macular degeneration Ana S. Falcão, Margarida Pedro, Sandra Tenreiro, and Miguel C. Seabra (NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal)

11:30 – 12:00 | Targeting pyroptosis: Exploring the role of mimethyl fumarate in TAU-driven neuroinflammation and neurodegeneration Ignacio Silva-Llanes, Lilia A. Smith, Aaron Abdelkader- Guillén, José Jiménez-Villegas, David Sarrió, Gema MorenoBueno, and Isabel Lastres-Becker (Instituto de Investigaciones Biomédicas “Sols-Morreale” UAM-CSIC, Instituto de Investigación Sanitaria La Paz (IdiPaz), Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red, Área Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Madrid, Spain)

12:00 – 12:30 | Dissecting oxidation-dependent and oxidation-independent components of thyroid autoregulation Georgios Psarias, Panos G. Ziros, Dionysios V. Chartoumpekis, and Gerasimos P. Sykiotis (Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland)

12:30 – 13:00 | Targeting transcription factor NRF2 for brain protective therapy in Alzheimer’s disease Antonio Cuadrado, Daniel Carnicero-Senabre, Angel J. García-Yagüe, Marta Olazabal-Chias, Eduardo Cazalla, José Jiménez-Villegas, Raquel Fernández-Ginés, Maribel Escoll and Ana I. Rojo (Department of Biochemistry, Medical School, Autonomous University of Madrid, Madrid, Spain)

14:30 – 15:00 | Mitochondrial transplantation activates NRF2 to restore cardiac function in heart failure Leila Aryan, Suatnur Şık, Ibrahim Turkel, Firat Akat, Gokhan Burcin Kubat, Erkan Tuncay (Department of Biophysics, Ankara University, Faculty of Medicine, and Department of Mitochondria and Cellular Research, University of Health Sciences, Ankara, Turkiye)

15:00 – 15:30 | Thiosulfate as modulator of oxidative stress through NRF2 signalling Harry van Goor, Udo Mulder, Imran Ertugrul, Yang Luo, Florent Alagnat, Hannie Westra, and Nik Morton (University Medical Center Groningen, Groningen, the Netherlands)

15:30 – 16:00 | Endothelial deletion of miRNA-34a blocks aortic aneurysm development in NRF2 KO mice – focus on endothelial cell proliferation Aleksandra Kopacz, Damian Kloska, Anna Bar, Marta Targosz-Korecka, Dominik Cysewski, Kamil Awsiuk, Aleksandra Piechota-Polanczyk, Milena Cichon, Stefan Chlopicki, Alicja Jozkowicz, and Anna Grochot-Przeczek (Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland)

16:00 – 16:30 | NRF2 modulation in macrophages as therapeutic strategy for tendon healing in tendinopathy Noemi Mencarelli (Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy)

17:00 – 17:30 | Regulation of micrornas by NRF2 activation in fibrosis Sharadha Dayalan Naidu, Tom Dixon, John D. Hayes, and Albena T. Dinkova-Kostova (University of Dundee, Dundee, U.K.)

17:30 – 18:00 | NRF2 as a therapeutic target in ALS: Insights into RNA metabolism and redox homeostasis José Jiménez-Villegas, Daniel Carnicero-Senabre, Janine Kirby, Ana Mata, Susana Cadenas, Martin R. Turner, Andrea Malaspina, Pamela J. Shaw, Adrià Sicart, Ludo Van Den Bosch, Antonio Cuadrado, and Ana I. Rojo (Department of Biochemistry and Biomedical Research Institute “SolsMorreale” (UAM/CSIC), Madrid, Spain)

18:00 – 18:30 | Uncovering interactions between the NRF2 pathway and the plasticity of liver progenitor cells in liver diseases Silvia Calero-Pérez, Inés Barahona, Elena del Fresno, Laura Villamayor, Águeda González-Rodríguez, M. Pilar Valdecantos, and Ángela M. Valverde (Institute of Biomedical Research Sols-Morreale, Spanish National Research Council (CSIC-UAM), and Network for Biomedical Research in Diabetes and Associated Metabolic Diseases (CIBERDEM, ISCIII), Madrid, Spain)

18:30 – 19:00 | Persistent suppression of ferroptosis by NRF2 is essential for tumor maintenance Donna D. Zhang (Department of Molecular Medicine, UF Scripps, Jupiter, FL, USA)

Cost.

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

BenBedPhar CA20121.

Action details.

Grant Holder: Universidad Autónoma de Madrid
Start of Action: 19 October, 2021
End of Action: 18 October, 2025
Entry into force: DATE HERE
CSO approval date: 25 May 2021
Action email: info@benbedphar20257135.live-website.com